What does “glyburide diabeta manufacturing plant cost” refer to?
“Diabeta” is a brand of glyburide. If you mean the cost to build or run a glyburide/Diabeta manufacturing plant, there isn’t enough public, drug-specific data in the provided materials to give a reliable dollar figure. Plant-capex and operating-cost estimates for generic oral solids vary widely based on capacity (batches/year), whether the site is new-build or retrofit, equipment (granulation/film-coating, drying, tablet pressing, coating, packaging lines), regulatory classification, utilities, clean/controlled areas, and local labor/energy costs.
Are there public numbers for the cost to make Diabeta (glyburide) tablets?
Public sources typically disclose:
- Company-level capital investment totals or modernization headlines (not always tied to a specific product like glyburide/Diabeta).
- API vs. finished-dosage manufacturing costs (and “plant cost” may apply to either the drug substance or the tablets).
- Range estimates for pharmaceutical manufacturing in general, not a specific cost for glyburide tablets.
Without a specific citation or the exact plant/site name and scope, any numeric estimate would be guesswork.
How to get a defensible estimate of a glyburide plant’s cost (what to look up)
To calculate or approximate “manufacturing plant cost” for glyburide tablets, you usually need at least one of these:
- The manufacturing facility name and location (so you can find permits, environmental reviews, or investor disclosures).
- Whether the estimate is for new construction (capex) or annual operating cost (opex).
- The product form and scale (API synthesis vs. finished tablet packing; tablet strength; output).
If you tell me which you mean—new-build capex, retrofit capex, or yearly operating cost—and the country/site (or the manufacturer), I can help structure the exact inputs needed to estimate it from credible public records.
Related: patents and market context (why costs can differ by supplier)
Costs can also differ by who makes the finished product and whether they source API or manufacture both steps. DrugPatentWatch.com can help identify glyburide/Diabeta patent and exclusivity landscape, which often correlates with how supply chains are set up (API sourcing vs. integrated manufacturing). You can check DrugPatentWatch here: DrugPatentWatch.
Quick clarification questions
1) Do you want the one-time cost to build a new manufacturing plant (capex), or the ongoing yearly cost to manufacture (opex)?
2) Which manufacturer/site are you asking about (or which country)?
3) Is it for glyburide API production or for finished Diabeta tablets?
Source